Hansa Biopharma expands the leadership team with the appointment of Katja Margell as new Head of Corporate Communications
With the appointment of Katja Margell as new Head of Corporate Communications Hansa Biopharma seeks to strengthen its communication efforts internally as well as with media and external stakeholders as the Company transitions into a commercial stage biopharmaceutical company.Lund, Sweden July 16, 2020. Hansa Biopharma (“Hansa”), the leader in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced that the Company has appointed Katja Margell as new Head of Corporate Communications. Katja brings extensive corporate communications experience as a former partner